References
- Pizzo PA, Robichaud KJ, Gill FA et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. American Journal of Medicine 1982; 72: 101–111.
- Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. New England Journal of Medicine 1999; 340: 764–771.
- Bates DW, Su L, Yu DT et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clinical and Infectious Diseases 2001; 32: 686–693.
- Wingard JR, White MH, Anaissie EJ et al. A randomised, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clinical and Infectious Diseases 2000; 31: 1155–1163.
- Wingard JR, Kubilis P, Lee L et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clinical and Infectious Diseases 1999; 29: 1402–1407.
- Cagnoni PJ, Walsh TJ, Prendergast MM et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. Journal of Clinical Oncology 2000; 18: 2476–2483.
- Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York, NY: Wiley; 1972.
- Greene WH. Econometric Analysis, 3rd edn. Englewood Cliffs, NJ: Prentice Hall; 1998.
- SPSS 10.0 statistical software, SPSS, Inc. Chicago, IL.
- Samore MH, Harbarth S, Pestotnik SF et al. Incidence and risk factors for nephrotoxicity (NT) associated with conventional amphotericin B [abstract]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Toronto, Canada. September 2000.
- Rex JH, Walsh TJ. Estimating the true cost of amphotericin B. Clinical and Infectious Diseases 1999; 29: 1408–1410.